Centessa Pharmaceuticals plc (CNTA) Form SCHEDULE 13D — Jun 24, 2026
A Schedule 13D filing has been submitted by a group of reporting persons, led by Hannah E. Dunn and including other executives such as Joshua J. Dapice and Philip D. Dreyfuss, regarding their holdings in Centessa Pharmaceuticals plc.
Key figures
- Purchase Price Range
- $39.51 - $40.25
- Total Purchase Value Approx
- $85,500,000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.